Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 DDI Study with Caffeine and Fluvoxamine in Healthy Subjects
NCT05121714Phase 1Completed
- Sponsor
- Abivax
- Start
- Dec 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obefazimod in ulcerative colitis (UC) (2 arms), sponsored by Abivax. Primary endpoints: Peak Plasma Concentration of Caffeine at Day 17, Area Under the Plasma Concentration versus Time Curve of Caffeine at Day 17 and 2 more. Started Dec 2020; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05121714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121714.